Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of SPN-812 ER High Dose in Adolescents With ADHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03247556
Recruitment Status : Completed
First Posted : August 11, 2017
Last Update Posted : May 20, 2019
Sponsor:
Information provided by (Responsible Party):
Supernus Pharmaceuticals, Inc.

Brief Summary:
This study will evaluate the efficacy and safety of high doses of SPN-812 ER in adolescents (12-17 years old)

Condition or disease Intervention/treatment Phase
ADHD Drug: Placebo Drug: 400mg SPN-812 ER Drug: 600mg SPN-812 ER Phase 3

Detailed Description:
This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group study, to assess the efficacy and safety of SPN-812 ER as monotherapy for the treatment of children 12-17 years old with ADHD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 297 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of SPN 812 ER 400 and 600 mg Efficacy and Safety in Adolescents With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Actual Study Start Date : November 20, 2017
Actual Primary Completion Date : February 14, 2019
Actual Study Completion Date : February 14, 2019

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo qd
Drug: Placebo
Placebo will be administered once daily
Other Name: PBO

Experimental: 400mg SPN-812 ER
400mg SPN-812 ER qd
Drug: 400mg SPN-812 ER
SPN-812 ER high dose A will be administered once daily and compared to Placebo
Other Name: SPN-812 ER High Dose A

Experimental: 600mg SPN-812 ER
600mg SPN-812 ER qd
Drug: 600mg SPN-812 ER
SPN-812 ER high dose B will be administered once daily and compared to Placebo
Other Name: SPN-812 ER High Dose B




Primary Outcome Measures :
  1. Efficacy of SPN-812 ER assessed by ADHD-RS-5 Rating Sc [ Time Frame: 7 weeks ]
    Change from Baseline to End of Study in the ADHD-RS-5 tot


Secondary Outcome Measures :
  1. Effect of SPN-812 ER assessed by Conners 3 Rating Scale [ Time Frame: 7 weeks ]
    Change from Baseline to End of Study in Conners 3 Rating Scale Score

  2. Effect of SPN-812 ER assessed by 50% Responder Rate [ Time Frame: 7 weeks ]
    Percentage of subjects with at least a 50% improvement in ADHD-RS-5 total score from Baseline to End of Study

  3. Effect of SPN-812 ER assessed by ADHD-RS-5 subscores [ Time Frame: 7 weeks ]
    Change from Baseline to End of Study in hyperactivity/impulsivity and inattention subscales of ADHD-RS-5

  4. Effect of SPN-812 ER assessed by Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) [ Time Frame: 7 weeks ]
    Change from Baseline to End of Study in WFIRS-P Score

  5. Effect of SPN-812 ER assessed by Stress Index for Parents of Adolescents (SIPA) [ Time Frame: 7 weeks ]
    Change from Baseline to End of Study in SIPA Score

  6. Effect of SPN-812 ER assessed by Clinical Global Impression-Severity of Illness and Improvement (CGI-I) Scale [ Time Frame: 7 weeks ]
    Change from Baseline to End of Study in CGI-I score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Healthy male or female subjects, 12-17 years of age, inclusive.
  2. Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).
  3. Attention Deficit/Hyperactivity Disorder Rating Scale-5, Home Version: Adolescent, Investigator Administered and Scored (ADHD-RS-5) score of at least 28.
  4. CGI-S score of at least 4 at screening.
  5. Weight of at least 35 kg.
  6. Free of medication for the treatment of ADHD for at least one week prior to randomization and agreement to remain so throughout the study.
  7. Considered medically healthy by the Investigator via assessment of physical examination, medical history, clinical laboratory tests, vital signs, and electrocardiogram.
  8. Written informed consent obtained from the subject's parent or legal representative and informed assent from the subject, if applicable.
  9. Females of childbearing potential (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose, throughout the study:

    1. simultaneous use of male condom and intra-uterine contraceptive device placed at least four weeks prior to the first study drug administration
    2. surgically sterile male partner
    3. simultaneous use of male condom and diaphragm with spermicide
    4. established hormonal contraceptive

Exclusion Criteria:

  1. Current diagnosis of major psychiatric disorders. Subjects with Major Depressive Disorder are allowed in the study if the subject is free of episodes both currently and for the last six months.
  2. Current diagnosis of major neurological disorders. Subjects with seizures or a history of seizure disorder within the immediate family (siblings, parents), or a history of seizure-like events are excluded from the study.
  3. Current diagnosis of significant systemic disease.
  4. Evidence of suicidality (defined as either active suicidal plan/intent or active suicidal thoughts, or more than one lifetime suicide attempt) within the six months before Screening or at Screening.
  5. BMI greater than 95th percentile for the appropriate age and gender.
  6. History of an allergic reaction to viloxazine or related drugs.
  7. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in this study.
  8. Subjects who received any investigational drug within the longer of 30 days or 5 half-lives prior to Day 1 dosing of SM.
  9. Any reason, which, in the opinion of the Investigator, would prevent the subject from participating in the study.
  10. Positive drug screen at the Screening Visit. A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening; the subject will be required to discontinue the stimulant for the study, beginning at least one week prior to the Baseline Visit.
  11. Pregnancy or refusal to practice abstinence or acceptable birth control during the study (for female subjects of childbearing potential)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03247556


Locations
Layout table for location information
United States, California
Alliance for Wellness dba Alliance for Research
Long Beach, California, United States, 90807
United States, Colorado
MCB Clinical Research Centers, LLC
Colorado Springs, Colorado, United States, 80910
United States, Florida
Meridien Research at Florida Clinical Research Center
Bradenton, Florida, United States, 34201
Innovative Clinical Research, Inc
Lauderhill, Florida, United States, 33319
Miami Clinical Research
Miami, Florida, United States, 33155
APG Research, LLC
Orlando, Florida, United States, 32803
United States, Georgia
iResearch Atlanta
Decatur, Georgia, United States, 30030
United States, Oklahoma
IPS Research
Oklahoma City, Oklahoma, United States, 73103
Paradigm Research Professionals
Oklahoma City, Oklahoma, United States, 73118
United States, South Carolina
Carolina Clinical Trials, Inc.
Charleston, South Carolina, United States, 29407
United States, Texas
Gadolin Research, LLC
Beaumont, Texas, United States, 77702
Bayou City Research Corporation
Houston, Texas, United States, 77006
Dicovery MM Services Inc. Houston
Houston, Texas, United States, 77061
United States, Utah
Ericksen Research & Development
Clinton, Utah, United States, 84015
Sponsors and Collaborators
Supernus Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Stefan Schwabe, MD Supernus Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Supernus Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03247556    
Other Study ID Numbers: 812P304
First Posted: August 11, 2017    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No